Fact and fiction in tuberculosis vaccine research: 10 years later
Summary Tuberculosis is one of the most deadly infectious diseases. The situation is worsening because of co-infection with HIV and increased occurrence of drug resistance. Although the BCG vaccine has been in use for 90 years, protection is insufficient; new vaccine candidates are therefore needed....
Gespeichert in:
| Veröffentlicht in: | The Lancet infectious diseases 2011-08, Vol.11 (8), p.633-640 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 640 |
|---|---|
| container_issue | 8 |
| container_start_page | 633 |
| container_title | The Lancet infectious diseases |
| container_volume | 11 |
| creator | Kaufmann, Stefan HE, Dr |
| description | Summary Tuberculosis is one of the most deadly infectious diseases. The situation is worsening because of co-infection with HIV and increased occurrence of drug resistance. Although the BCG vaccine has been in use for 90 years, protection is insufficient; new vaccine candidates are therefore needed. 12 potential vaccines have gone into clinical trials. Ten are aimed at prevention of tuberculosis and, of these, seven are subunit vaccines either as adjuvanted or viral-vectored antigens. These vaccines would be boosters of BCG-prime vaccination. Three vaccines are recombinant BCG constructs—possible replacements for BCG. Additional vaccine candidates will enter clinical trials in the near future, including postexposure vaccines for individuals with latent infection. In the long term, vaccines that prevent or eradicate infection with Mycobacterium tuberculosis would be the best possible option. Improved knowledge of immunology, molecular microbiology, cell biology, biomics, and biotechnology has paved the way towards an effective and safe vaccine against tuberculosis. The pipeline of new vaccine candidates from preclinical to clinical testing could be accelerated by development of biomarkers that can predict the clinical outcome of tuberculosis. |
| doi_str_mv | 10.1016/S1473-3099(11)70146-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_904485985</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1473309911701463</els_id><sourcerecordid>904485985</sourcerecordid><originalsourceid>FETCH-LOGICAL-c508t-a556bd329eadbb3fb8e4bb6ae46afc008f90bc7c3891b1467f15d82068707a613</originalsourceid><addsrcrecordid>eNqFkUFrFTEUhYMotlZ_ghIEURej904ymcSFUopVoeBCXYckcwdT5820yUzh_Xvz3jwrdNNVLuG7JznnMPYc4R0Cqvc_ULaiEmDMG8S3LaBUlXjAjsu1rKRs2of7eUWO2JOcLwGwRZCP2VGNrdFSiWN2eu7CzN3Y8T6GOU4jjyOfF08pLMOUY-Y3LoQ4Ek-UyaXw-wNH4NsyZj64mdJT9qh3Q6Znh_OE_Tr__PPsa3Xx_cu3s9OLKjSg58o1jfKdqA25znvRe03Se-VIKtcHAN0b8KENQhv0xUzbY9PpGpRuoXUKxQl7vepepel6oTzbTcyBhsGNNC3ZGpBSN0Y395JaAwoFWBfy5R3yclrSWGwUCIUURskCNSsU0pRzot5epbhxaWsR7K4Lu-_C7oK2iHbfhRVl78VBfPEb6m63_oVfgFcHwOXghj65McT8n5OyxGJ2zj-tHJV4byIlm0OkMVAXE4XZdlO89ysf7yiEIY6xPPqHtpRvTaPNtYVVZKeBuFcQ4i9aBbgg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>881343964</pqid></control><display><type>article</type><title>Fact and fiction in tuberculosis vaccine research: 10 years later</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>ProQuest Central UK/Ireland</source><creator>Kaufmann, Stefan HE, Dr</creator><creatorcontrib>Kaufmann, Stefan HE, Dr</creatorcontrib><description>Summary Tuberculosis is one of the most deadly infectious diseases. The situation is worsening because of co-infection with HIV and increased occurrence of drug resistance. Although the BCG vaccine has been in use for 90 years, protection is insufficient; new vaccine candidates are therefore needed. 12 potential vaccines have gone into clinical trials. Ten are aimed at prevention of tuberculosis and, of these, seven are subunit vaccines either as adjuvanted or viral-vectored antigens. These vaccines would be boosters of BCG-prime vaccination. Three vaccines are recombinant BCG constructs—possible replacements for BCG. Additional vaccine candidates will enter clinical trials in the near future, including postexposure vaccines for individuals with latent infection. In the long term, vaccines that prevent or eradicate infection with Mycobacterium tuberculosis would be the best possible option. Improved knowledge of immunology, molecular microbiology, cell biology, biomics, and biotechnology has paved the way towards an effective and safe vaccine against tuberculosis. The pipeline of new vaccine candidates from preclinical to clinical testing could be accelerated by development of biomarkers that can predict the clinical outcome of tuberculosis.</description><identifier>ISSN: 1473-3099</identifier><identifier>EISSN: 1474-4457</identifier><identifier>DOI: 10.1016/S1473-3099(11)70146-3</identifier><identifier>PMID: 21798463</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>London: Elsevier Ltd</publisher><subject>Bacterial diseases ; BCG ; Biological and medical sciences ; biomarkers ; Biomarkers - blood ; Biotechnology ; Clinical trials ; Drug resistance ; Human bacterial diseases ; Human immunodeficiency virus ; Humans ; Immunology ; Infectious Disease ; Infectious diseases ; Latent infection ; Medical sciences ; Microbiology ; Mycobacterium tuberculosis ; Mycobacterium tuberculosis - immunology ; Public health ; Tuberculosis ; Tuberculosis - blood ; Tuberculosis - immunology ; Tuberculosis - prevention & control ; Tuberculosis and atypical mycobacterial infections ; Tuberculosis Vaccines - administration & dosage ; Tuberculosis Vaccines - immunology ; Vaccination - methods ; Vaccination - nursing ; Vaccination - standards ; Vaccines</subject><ispartof>The Lancet infectious diseases, 2011-08, Vol.11 (8), p.633-640</ispartof><rights>Elsevier Ltd</rights><rights>2011 Elsevier Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Aug 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c508t-a556bd329eadbb3fb8e4bb6ae46afc008f90bc7c3891b1467f15d82068707a613</citedby><cites>FETCH-LOGICAL-c508t-a556bd329eadbb3fb8e4bb6ae46afc008f90bc7c3891b1467f15d82068707a613</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/881343964?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,777,781,3538,27906,27907,45977,64365,64367,64369,72219</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24400891$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21798463$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kaufmann, Stefan HE, Dr</creatorcontrib><title>Fact and fiction in tuberculosis vaccine research: 10 years later</title><title>The Lancet infectious diseases</title><addtitle>Lancet Infect Dis</addtitle><description>Summary Tuberculosis is one of the most deadly infectious diseases. The situation is worsening because of co-infection with HIV and increased occurrence of drug resistance. Although the BCG vaccine has been in use for 90 years, protection is insufficient; new vaccine candidates are therefore needed. 12 potential vaccines have gone into clinical trials. Ten are aimed at prevention of tuberculosis and, of these, seven are subunit vaccines either as adjuvanted or viral-vectored antigens. These vaccines would be boosters of BCG-prime vaccination. Three vaccines are recombinant BCG constructs—possible replacements for BCG. Additional vaccine candidates will enter clinical trials in the near future, including postexposure vaccines for individuals with latent infection. In the long term, vaccines that prevent or eradicate infection with Mycobacterium tuberculosis would be the best possible option. Improved knowledge of immunology, molecular microbiology, cell biology, biomics, and biotechnology has paved the way towards an effective and safe vaccine against tuberculosis. The pipeline of new vaccine candidates from preclinical to clinical testing could be accelerated by development of biomarkers that can predict the clinical outcome of tuberculosis.</description><subject>Bacterial diseases</subject><subject>BCG</subject><subject>Biological and medical sciences</subject><subject>biomarkers</subject><subject>Biomarkers - blood</subject><subject>Biotechnology</subject><subject>Clinical trials</subject><subject>Drug resistance</subject><subject>Human bacterial diseases</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Immunology</subject><subject>Infectious Disease</subject><subject>Infectious diseases</subject><subject>Latent infection</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Mycobacterium tuberculosis</subject><subject>Mycobacterium tuberculosis - immunology</subject><subject>Public health</subject><subject>Tuberculosis</subject><subject>Tuberculosis - blood</subject><subject>Tuberculosis - immunology</subject><subject>Tuberculosis - prevention & control</subject><subject>Tuberculosis and atypical mycobacterial infections</subject><subject>Tuberculosis Vaccines - administration & dosage</subject><subject>Tuberculosis Vaccines - immunology</subject><subject>Vaccination - methods</subject><subject>Vaccination - nursing</subject><subject>Vaccination - standards</subject><subject>Vaccines</subject><issn>1473-3099</issn><issn>1474-4457</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkUFrFTEUhYMotlZ_ghIEURej904ymcSFUopVoeBCXYckcwdT5820yUzh_Xvz3jwrdNNVLuG7JznnMPYc4R0Cqvc_ULaiEmDMG8S3LaBUlXjAjsu1rKRs2of7eUWO2JOcLwGwRZCP2VGNrdFSiWN2eu7CzN3Y8T6GOU4jjyOfF08pLMOUY-Y3LoQ4Ek-UyaXw-wNH4NsyZj64mdJT9qh3Q6Znh_OE_Tr__PPsa3Xx_cu3s9OLKjSg58o1jfKdqA25znvRe03Se-VIKtcHAN0b8KENQhv0xUzbY9PpGpRuoXUKxQl7vepepel6oTzbTcyBhsGNNC3ZGpBSN0Y395JaAwoFWBfy5R3yclrSWGwUCIUURskCNSsU0pRzot5epbhxaWsR7K4Lu-_C7oK2iHbfhRVl78VBfPEb6m63_oVfgFcHwOXghj65McT8n5OyxGJ2zj-tHJV4byIlm0OkMVAXE4XZdlO89ysf7yiEIY6xPPqHtpRvTaPNtYVVZKeBuFcQ4i9aBbgg</recordid><startdate>20110801</startdate><enddate>20110801</enddate><creator>Kaufmann, Stefan HE, Dr</creator><general>Elsevier Ltd</general><general>Lancet Publishing Group</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20110801</creationdate><title>Fact and fiction in tuberculosis vaccine research: 10 years later</title><author>Kaufmann, Stefan HE, Dr</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c508t-a556bd329eadbb3fb8e4bb6ae46afc008f90bc7c3891b1467f15d82068707a613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Bacterial diseases</topic><topic>BCG</topic><topic>Biological and medical sciences</topic><topic>biomarkers</topic><topic>Biomarkers - blood</topic><topic>Biotechnology</topic><topic>Clinical trials</topic><topic>Drug resistance</topic><topic>Human bacterial diseases</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Immunology</topic><topic>Infectious Disease</topic><topic>Infectious diseases</topic><topic>Latent infection</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Mycobacterium tuberculosis</topic><topic>Mycobacterium tuberculosis - immunology</topic><topic>Public health</topic><topic>Tuberculosis</topic><topic>Tuberculosis - blood</topic><topic>Tuberculosis - immunology</topic><topic>Tuberculosis - prevention & control</topic><topic>Tuberculosis and atypical mycobacterial infections</topic><topic>Tuberculosis Vaccines - administration & dosage</topic><topic>Tuberculosis Vaccines - immunology</topic><topic>Vaccination - methods</topic><topic>Vaccination - nursing</topic><topic>Vaccination - standards</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaufmann, Stefan HE, Dr</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaufmann, Stefan HE, Dr</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fact and fiction in tuberculosis vaccine research: 10 years later</atitle><jtitle>The Lancet infectious diseases</jtitle><addtitle>Lancet Infect Dis</addtitle><date>2011-08-01</date><risdate>2011</risdate><volume>11</volume><issue>8</issue><spage>633</spage><epage>640</epage><pages>633-640</pages><issn>1473-3099</issn><eissn>1474-4457</eissn><coden>LANCAO</coden><abstract>Summary Tuberculosis is one of the most deadly infectious diseases. The situation is worsening because of co-infection with HIV and increased occurrence of drug resistance. Although the BCG vaccine has been in use for 90 years, protection is insufficient; new vaccine candidates are therefore needed. 12 potential vaccines have gone into clinical trials. Ten are aimed at prevention of tuberculosis and, of these, seven are subunit vaccines either as adjuvanted or viral-vectored antigens. These vaccines would be boosters of BCG-prime vaccination. Three vaccines are recombinant BCG constructs—possible replacements for BCG. Additional vaccine candidates will enter clinical trials in the near future, including postexposure vaccines for individuals with latent infection. In the long term, vaccines that prevent or eradicate infection with Mycobacterium tuberculosis would be the best possible option. Improved knowledge of immunology, molecular microbiology, cell biology, biomics, and biotechnology has paved the way towards an effective and safe vaccine against tuberculosis. The pipeline of new vaccine candidates from preclinical to clinical testing could be accelerated by development of biomarkers that can predict the clinical outcome of tuberculosis.</abstract><cop>London</cop><pub>Elsevier Ltd</pub><pmid>21798463</pmid><doi>10.1016/S1473-3099(11)70146-3</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-3099 |
| ispartof | The Lancet infectious diseases, 2011-08, Vol.11 (8), p.633-640 |
| issn | 1473-3099 1474-4457 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_904485985 |
| source | MEDLINE; Elsevier ScienceDirect Journals; ProQuest Central UK/Ireland |
| subjects | Bacterial diseases BCG Biological and medical sciences biomarkers Biomarkers - blood Biotechnology Clinical trials Drug resistance Human bacterial diseases Human immunodeficiency virus Humans Immunology Infectious Disease Infectious diseases Latent infection Medical sciences Microbiology Mycobacterium tuberculosis Mycobacterium tuberculosis - immunology Public health Tuberculosis Tuberculosis - blood Tuberculosis - immunology Tuberculosis - prevention & control Tuberculosis and atypical mycobacterial infections Tuberculosis Vaccines - administration & dosage Tuberculosis Vaccines - immunology Vaccination - methods Vaccination - nursing Vaccination - standards Vaccines |
| title | Fact and fiction in tuberculosis vaccine research: 10 years later |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T09%3A04%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fact%20and%20fiction%20in%20tuberculosis%20vaccine%20research:%2010%20years%20later&rft.jtitle=The%20Lancet%20infectious%20diseases&rft.au=Kaufmann,%20Stefan%20HE,%20Dr&rft.date=2011-08-01&rft.volume=11&rft.issue=8&rft.spage=633&rft.epage=640&rft.pages=633-640&rft.issn=1473-3099&rft.eissn=1474-4457&rft.coden=LANCAO&rft_id=info:doi/10.1016/S1473-3099(11)70146-3&rft_dat=%3Cproquest_cross%3E904485985%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=881343964&rft_id=info:pmid/21798463&rft_els_id=1_s2_0_S1473309911701463&rfr_iscdi=true |